Plasma lipoprotein-associated phospholipase A2 level and its clinical significance in patients with stroke

doi:10.3969/j.issn.1673-8640.2014.03.012

Abstract

Abstract:

Objective　To investigate the changes of lipoprotein-associated phospholipase A2 (Lp-PLA2) level in patients with stroke,and to research the correlation with the volume of cerebral infarction and the severity of neurological impairment in patients with ischemic stroke. Methods　A total of 180 ischemic stroke patients,165 hemorrhagic stroke patients and 105 healthy subjects (healthy control group) were enrolled. By enzyme-linked immunosorbent assay (ELISA),the plasma Lp-PLA2 levels were determined,and the receiver operating characteristic (ROC) curve was used to evaluate the efficacy of Lp-PLA2 in the diagnosis of ischemic stroke and hemorrhagic stroke. The blood lipids [total cholesterol (TC),triglyceride (TG),high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C)],glucose (Glu) and fibrinogen (FIB) were determined. The volumes of cerebral infarction were measured by cranium magnetic resonance imaging,and the severities of neurological impairment were assessed by the National Institutes of Health Stroke Scale.The correlation of plasma Lp-PLA2 with the National Institutes of Health Stroke Scale was analyzed. Results　The levels of Lp-PLA2,TC,HDL-C,LDL-C and FIB among ischemic stroke,hemorrhagic stroke and healthy control groups had statistical significance (P<0.05). TG and Glu had no statistical significance between ischemic stroke and hemorrhagic stroke groups (P=0.133 and 0.067),and there were statistical significance with those in healthy control group(P<0.05). The area under the ROC curve (AUC) was 0.905,and the optimal cut-off value was 42.35 μg/L. The diagnostic sensitivity and specificity of plasma Lp-PLA2 were 81.5% and 80.0%. Plasma Lp-PLA2 increased with the increase of the volume of cerebral infarction,but it had no statistical significance(H=0.372,P=0.719).Spearman correlation analysis showed that plasma Lp-PLA2 had significant correlation with the National Institutes of Health Stroke Scale(P<0.05). Conclusions　Plasma Lp-PLA2 increases significantly in patients with ischemic stroke,and it is significantly correlated with the National Institutes of Health Stroke Scale. Plasma Lp-PLA2 is an independent risk factor for ischemic stroke,and it may be a prediction index of ischemic stroke and a useful parameter for the severity of patient's condition.

Key words: Lipoprotein-associated phospholipase A2, Stroke, Atherosclerosis

CLC Number:

Q556

YE Yun，LI Suliang. Plasma lipoprotein-associated phospholipase A2 level and its clinical significance in patients with stroke[J]. , 2014, 29(3): 249-253.

References

[1] Tay SY,Ampil ER,Chen CP,et al. The relationship between homocysteine,cognition and stroke subtypes in acute stroke[J]. J Neurol Sci,2006,250(1-2):58-61.
[2] Kim JY,Hyun YJ,Jang Y,et al.Lipoprotein-associated phospholipase A2 activity is associated with coronary artery disease and markers of oxidative stress:a case-control study[J].Am J Clin Nutr,2008,88(3):630-637.
[3] Brilakis ES,Khera A,Saeed B,et al.Association of lipoprotein-associated phospholipase A2 mass and activity with coronary and aortic atherosclerosis:finding from the Dallas Heart Study[J].Clin Chem,2008,54(12):1975-1981.
[4] Mannheim D,Herrmann J,Versari D,et al. Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques[J]. Stroke,2008,39(5):1448-1455.
[5] 各类脑血管病诊断要点[J].中华神经科杂志,1996,42(6):60-61.
[6] Stewart RA,White HD. The role of lipoprotein-associated phospholipase a₂ as a marker and potential therapeutic target in atherosclerosis[J]. Curr Atheroscler Rep,2011,13(2):132-137.
[7] Colley KJ,Wolfert RL,Cobble ME. Lipoprotein associated phospholipase A(2): role in atherosclerosis and utility as a biomarker for cardiovascular risk[J]. EPMA J,2011,2(1):27-38.
[8] Ninio E,Tregouet D,Carrier JL,et al. Platelet-activating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease[J]. Hum Mol Genet,2004,13(13):1341-1351.
[9] Serruys PW,García-García HM,Buszman P,et al. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque[J]. Circulation,2008,118(11):1172-1182.
[10] Jenny NS,Solomon C,Cushman M,et al. Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and risk of cardiovascular disease in older adults:results from the Cardiovascular Health Study[J]. Atherosclerosis,2010,209(2):528-532.
[11] Mannheim D,Herrmann J,Versari D,et al. Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques[J]. Stroke,2008,39(5):1448-1455.
[12] 邬建民,张力.脂蛋白相关磷脂酶A2在冠心病患者严重程度评估中的应用[J].检验医学,2011,26(2):85-87.
[13] Macphee CH,Nelson J,Zalewski A. Role of lipo-protein-associated phospholipase A2 in atherosclerosis and its potential as a therapeutic target[J]. Curr Opin Pharmacol,2006,6(2):154-161.

[1]	ZHAO Jing, WANG Pei, LU Dandan, QI Dandan, LI Xuan. Expression levels of serum miR-4443 and TRAF4 in patients with hemorrhagic stroke [J]. Laboratory Medicine, 2023, 38(5): 413-418.
[2]	WU Ying, ZHANG Lihong, GAO Yin. Predictive value of high-density lipoprotein cholesterol on the risk of cerebral ischemic stroke in type 2 diabetes mellitus patients [J]. Laboratory Medicine, 2023, 38(11): 1052-1056.
[3]	ZHU Qian, ZHU Lifang, MA Caiyun, YAO Jie. Relation of serum miR-140-5p and PGC-1α mRNA expression with vascular cognitive impairment in acute ischemic stroke patients [J]. Laboratory Medicine, 2023, 38(11): 1069-1074.
[4]	MA Jianguo, ZHU Xiaolin, DING Yongguang, YIN Meng, LI Hongchun. Predictive values of red blood cell distribution width and myocardial markers for acute myocardial infarction in patients with CAS [J]. Laboratory Medicine, 2022, 37(12): 1164-1168.
[5]	KONG Fanbin, YUAN Yong, JI Yong, LI Zheng, CHEN Qi, WU Xiaoming, GAO Hui. Correlation between serum retinol binding protein 4,homocysteine and blood lipid with atherosclerosis [J]. Laboratory Medicine, 2021, 36(5): 467-470.
[6]	ZHAO Jingjing, ZHANG Peng, ZHOU Yong, CAO Yingping, HUANG Zhihu, FU Shengmiao, WANG Yuming, HONG Guolin, SHEN Jun, ZHENG Lei. A preliminary study on Lp-PLA2 and its relationship with LDL-C and hs-CRP in southern China [J]. Laboratory Medicine, 2021, 36(12): 1222-1228.
[7]	LI Jinyi, LI Chunlei, JIA Yonglin, JIA Dongpei. Plasma ADAMTS-7 level and its relationship with prognosis in patients with acute ischemic stroke [J]. Laboratory Medicine, 2021, 36(10): 1033-1038.
[8]	LIANG Tao, LIU Feng, ZHANG Detai, WANG Lin, HU Lihua. Investigation of lipoprotein-associated phospholipase A2 levels among apparently healthy population in Wuhan [J]. Laboratory Medicine, 2020, 35(9): 889-894.
[9]	CHEN Yabin, CAI Hehui, ZHANG Jianming, SU Yongfa, ZHANG Zhishan. Relationship between plasma small dense low-density lipoprotein and ischemic stroke [J]. Laboratory Medicine, 2020, 35(5): 409-413.
[10]	LU Yide, WU Jianing, PENG Yibing. Clinical application of serum lipoprotein-associated phospholipase A₂ level in patients with acute cerebral infarction [J]. Laboratory Medicine, 2020, 35(2): 129-133.
[11]	LIU Xiaoni, WANG Ying, LI Taotao, MA Xiaomin, ZHAO Huanlao. Correlation of insulin resistance index and chronic inflammation index in type 2 diabetes mellitus patients with metabolic syndrome [J]. Laboratory Medicine, 2019, 34(9): 826-830.
[12]	CAO Ming, WANG Qijun. Influence of plasma homocysteine level change on atherosclerosis in H-type hypertension patients [J]. Laboratory Medicine, 2019, 34(11): 1007-1010.
[13]	WANG Kaijuan, LI Tiewei, WANG Zongjian, CHEN Xi, GAO Xiaojing, LIN Yahui, ZHOU Zhou, KANG Jinsuo. Correlation between high-sensitivity cardiac troponin T and the characteristics of coronary atherosclerosis [J]. Laboratory Medicine, 2019, 34(1): 11-18.
[14]	BO Lei, SHAN Jigang, ZHAO Zhiwen. Research progress of myeloperoxidase in cardiovascular diseases [J]. Laboratory Medicine, 2017, 32(8): 738-743.
[15]	JIA Keke, QIN Yanfei, YANG Shuo, ZHANG Jie. Comparison between a lipoprotein （a） particle concentration assay and 2 kinds of lipoprotein （a） mass concentration assays [J]. Laboratory Medicine, 2017, 32(7): 570-576.